Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Clin Pharmacol Res ; 25(3): 133-44, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16366421

RESUMEN

The weight-loss efficacy of a novel, water-soluble, calcium-potassium salt of (-)-hydroxycitric acid (HCA-SX) was re-examined in 90 obese subjects (BMI: 30-50.8 kg/m2). We combined data from two previously reported randomized, double-blind, placebo-controlled clinical studies in order to achieve a better statistical evaluation based on a larger population. This re-examination of data also allowed us to reflect more intensely on various aspects of weight loss studies. Subjects were randomly divided into three groups: group A received a daily dose of HCA-SX 4, 667 mg (providing 2,800 mg HCA per day); group B was given a daily dose of a combination of HCA-SX 4,667 mg, niacin-bound chromium (NBC) 4 mg (providing 400 microg elemental chromium), and Gymnema sylvestre extract (GSE) 400 mg (providing 100 mg gymnemic acid); and group C received a placebo in three equally divided doses 30-60 min before each meal. All subjects were provided a 2,000 kcal diet/day and participated in a supervised walking program for 30 min/day, 5 days/week. Eighty-two subjects completed the study. At the end of 8 weeks, in group A, both body weight and BMI decreased by 5.4%, low-density lipoprotein and triglycerides levels were reduced by 12.9% and 6.9%, respectively, while high-density lipoprotein levels increased by 8.9%, serum leptin levels decreased by 38%, serotonin levels increased by 44.5% and urinary excretion of fat metabolites increased by 32-109%. Group B demonstrated similar beneficial changes, but generally to a greater extent. No significant adverse effects were observed. The combined results confirm that HCA-SX and, to a greater degree, the combination of HCA-SX plus NBC and GSE reduce body weight and BMI, suppress appetite, improve blood lipid profiles, increase serum leptin and serotonin levels and increase fat oxidation more than placebo. We conclude that dosage levels, timing of administration, subject compliance and bioavailability of HCA-SX significantly affect results and that when taken as directed, HCA-SX is a highly effective adjunct to healthy weight control.


Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Calcio/química , Citratos/uso terapéutico , Obesidad/tratamiento farmacológico , Potasio/química , Adulto , Fármacos Antiobesidad/administración & dosificación , Fármacos Antiobesidad/química , Índice de Masa Corporal , Peso Corporal/efectos de los fármacos , Cromo/administración & dosificación , Cromo/uso terapéutico , Citratos/administración & dosificación , Citratos/química , Método Doble Ciego , Quimioterapia Combinada , Gymnema sylvestre/química , Humanos , Leptina/sangre , Lípidos/sangre , Persona de Mediana Edad , Niacina/administración & dosificación , Niacina/uso terapéutico , Preparaciones de Plantas/administración & dosificación , Preparaciones de Plantas/uso terapéutico , Serotonina/sangre , Solubilidad , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA